Cargando…

Letter to the editor: naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date

Detalles Bibliográficos
Autor principal:	Buehler, Anna M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4293294/ https://www.ncbi.nlm.nih.gov/pubmed/25609921 http://dx.doi.org/10.2147/DDDT.S77881

Ejemplares similares

Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date
por: Caixàs, Assumpta, et al.
Publicado: (2014)

Quality of life, binge eating and sexual function in participants treated for obesity with sustained release naltrexone/bupropion
por: Halseth, A., et al.
Publicado: (2018)

Method‐of‐use study of naltrexone sustained release (SR)/bupropion SR on body weight in individuals with obesity
por: Halseth, Amy, et al.
Publicado: (2016)

Effects of Naltrexone Sustained- Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes
por: Hollander, Priscilla, et al.
Publicado: (2013)

Naltrexone/Bupropion: Contrave®; Naltrexone SR/Bupropion SR
Publicado: (2012)

Use of Contrave, Naltrexone with Bupropion, Bupropion, or Naltrexone and Major Adverse Cardiovascular Events: A Systematic Literature Review
por: Dahlberg, Sarah, et al.
Publicado: (2022)

Naltrexone/Bupropion extended release‐induced weight loss is independent of nausea in subjects without diabetes
por: Hong, K., et al.
Publicado: (2016)

Probing the Release of Bupropion and Naltrexone Hydrochloride Salts from Biopolymeric Matrices of Diverse Chemical Structures
por: Siamidi, Angeliki, et al.
Publicado: (2021)

Assessment of the effectiveness of sustained release Bupropion and intensive physician advice in smoking cessation
por: Singh, Pranav, et al.
Publicado: (2010)

Psychiatric adverse events and effects on mood with prolonged-release naltrexone/bupropion combination therapy: a pooled analysis
por: Pi-Sunyer, Xavier, et al.
Publicado: (2019)

Naltrexone HCI/bupropion HCI for chronic weight management in obese adults: patient selection and perspectives
por: Tek, Cenk
Publicado: (2016)

Maternally Administered Sustained-Release Naltrexone in Rats Affects Offspring Neurochemistry and Behaviour in Adulthood
por: Farid, Waleed O., et al.
Publicado: (2012)

Effects of topiramate, bupropion and naltrexone isolated or combined on subcutaneous adipose tissue in obese rats
por: Scudeler, Monica Alhadas, et al.
Publicado: (2022)

Effect of combined naltrexone and bupropion therapy on the brain’s functional connectivity
por: Wang, Gene-Jack, et al.
Publicado: (2018)

Potential Role of Bupropion Sustained Release for Cancer-Related Fatigue: a Double-Blind, Placebo-Controlled Study
por: Ashrafi, Farzaneh, et al.
Publicado: (2018)

Role of Bupropion and Naltrexone in Managing Depression With Polycystic Ovary Syndrome: A Case Report and Literature Review
por: Shah, Kaushal, et al.
Publicado: (2020)

Effect of combined naltrexone and bupropion therapy on the brain's reactivity to food cues
por: Wang, G-J, et al.
Publicado: (2014)

Naltrexone/Bupropion Combination Therapy in Overweight or Obese Patients With Major Depressive Disorder: Results of a Pilot Study
por: McElroy, Susan L., et al.
Publicado: (2013)

Successful naltrexone-bupropion treatment after several treatment failures in a patient with severe monogenic obesity
por: Welling, Mila S., et al.
Publicado: (2023)

Naltrexone and Bupropion Combination Treatment for Smoking Cessation and Weight Loss in Patients With Schizophrenia
por: Lyu, Xuechan, et al.
Publicado: (2018)

Naltrexone extended-release injection: an option for the management of opioid abuse
por: Taylor, Robert, et al.
Publicado: (2011)

In reply to the Letter to the Editor “Leadership to improve consistency in echocardiography date”
por: Marriner, Mieko
Publicado: (2020)

The relationship between early weight loss and weight loss maintenance with naltrexone-bupropion therapy
por: le Roux, Carel W., et al.
Publicado: (2022)

Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial
por: Wharton, Sean, et al.
Publicado: (2021)

Response on Article “A Sustained-Release Nanosystem with MRSA Biofilm-Dispersing and -Eradicating Abilities Accelerates Diabetic Ulcer Healing” [Letter]
por: Panjaitan, Novaria Sari Dewi, et al.
Publicado: (2023)

Comparison of sustained-release morphine with sustained-release oxycodone in advanced cancer patients
por: Lauretti, G R, et al.
Publicado: (2003)

A Randomized, Phase 3 Trial of Naltrexone SR/Bupropion SR on Weight and Obesity-related Risk Factors (COR-II)
por: Apovian, Caroline M, et al.
Publicado: (2013)

Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail
por: Velasquez, Melissa, et al.
Publicado: (2019)

Letter to Editor - What makes a sustainable 24/7/365 Interventional radiology service
por: TEH, Hui Seong
Publicado: (2019)

Sustained-Release Corticosteroid Options
por: Cabrera, Mariana, et al.
Publicado: (2014)

Letter to the Editor [Letter]
por: Félix, Sylvie
Publicado: (2021)

Response on Article “A Sustained-Release Nanosystem with MRSA Biofilm-Dispersing and -Eradicating Abilities Accelerates Diabetic Ulcer Healing” [Response to Letter]
por: Li, Zhiqing
Publicado: (2023)

Simultaneous determination of naltrexone and bupropion in their co-formulated tablet utilizing green chromatographic approach with application to human urine
por: Abdel-Gawad, Sherif A., et al.
Publicado: (2018)

Urinary Incontinence during Sleep Associated with Extended Release Form of Bupropion HCI
por: Izci, Filiz, et al.
Publicado: (2015)

Morphine Sustained Release Tablets Becoming Ghost Pill: A Palliative Conundrum
por: Garg, Keshav Kumar, et al.
Publicado: (2022)

Concurrent Improvement in Both Binge Eating and Depressive Symptoms with Naltrexone/Bupropion Therapy in Overweight or Obese Subjects with Major Depressive Disorder in an Open-Label, Uncontrolled Study
por: Guerdjikova, Anna I., et al.
Publicado: (2017)

Neural correlates of adherence to extended-release naltrexone pharmacotherapy in heroin dependence
por: Wang, A-L, et al.
Publicado: (2015)

Letter to the editor
por: Kanna, Balavenkatesh, et al.
Publicado: (2005)

Letter to the editor
por: Rosival, Viktor
Publicado: (2005)

Letter to the editor
por: Zühlke, LJ, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_qgafolmnn33h810vf54pe3e02h